Argenica Therapeutics Limited (AGN.AX)
ASX · AUD · Healthcare · Biotechnology
A$0.105 (+0.00%) as of
Key statistics
- Market cap
- 13.49M
- EPS (TTM)
- -0.0100
- Dividend yield
- 0.00%
- 52-week range
- 0.0870 – 0.3450
- Beta
- 1.08
- Revenue (TTM)
- 5.48M
- Profit margin
- -24.90%
- Volume
- 95.36k
About Argenica Therapeutics Limited
Argenica Therapeutics Limited, a biotechnology company, engages in the research and development of neuroprotective therapeutic drugs in Australia. Its lead product candidate is ARG-007, a neuroprotective peptide candidate, which is in phase 2 clinical trial to reduce brain tissue death after stroke and other types of brain injury. Argenica Therapeutics Limited was incorporated in 2019 and is based in Nedlands, Australia.
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- Nedlands, WA, Australia
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.